ERIN WALLER: Open Payments
NPI 1578036349 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$147 in 8 payments from 8 companies in 2025. Trend: 2023 $341 · 2024 $122 · 2025 $147
Food & beverage: $147
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Exeltis, USA Inc. | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Exact Sciences Corporation | 1 | $15 |
Products named: MYFEMBREE, CAPLYTA, Omnipod, Veozah, SLYND, Wegovy, TRINTELLIX, Cologuard Collection Kit.
Industry payments across LA — which companies pay providers there.
